Johnson & Johnson unit Janssen has presented the first data from the Phase III PERSEUS study at the annual meeting of the American Society of Hematology (ASH). 13 December 2023
Kite, a subsidiary of US biotech major Gilead Sciences, has announced the results of new analyses supporting the use of Tecartus (brexucabtagene autoleucel) in 12 December 2023
At the 65th American Society of Hematology (ASH) annual meeting, Gilead Sciences company Kite has announced results from a three-year follow-up analysis of the 12 December 2023
US pharma major Bristol Myers Squibb has announced the results of two early studies evaluating combinations of CELMoD agent golcadomide in non-Hodgkin lymphomas 12 December 2023
The Johnson & Johnson (NYSE.JNJ) subsidiary Janssen has presented new long-term follow-up data at the 2023 American Society of Hematology (ASH) Annual Meeting f 11 December 2023
Adding Sarclisa (isatuximab) to carfilzomib.lenalidomide and dexamethasone (KRd) caused a statistically significant improvement in the rate of minimal residual 11 December 2023
Britain’s largest drugmaker, AstraZeneca, has announced positive long-term results from the Phase III ALPHA trial at the annual meeting of the American Society 11 December 2023
US pharma major Bristol Myers Squibb has presented updated results from the primary analysis of the Phase III COMMANDS trial at the 2023 American Society of Hem 10 December 2023
With the end of the year approaching, it is again time for The American Society of Hematology (ASH) Annual Meeting, the last major pharmaceutical conference in 9 December 2023
US biotech major Regeneron added to its offering at this year’s American Society of Hematology (ASH) meeting with data on linvoseltamab in multiple myeloma. 13 December 2022
Eli Lilly’s (NYSE: LLY) oncology company, Loxo@Lilly, has announced updated clinical data from the global Phase I/II BRUIN trial of pirtobrutinib. 13 December 2022
USA-based Regeneron Pharmaceuticals (Nasdaq: REGN) has announced positive new and updated data from the Phase I ELM-1 and pivotal Phase II ELM-2 trial of its ly 12 December 2022
With Imbruvica (ibrutinib) sales of nearly $10 billion recorded by Janssen and AbbVie combined in 2021, the blood cancer drug has already changed the standard o 12 December 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.